Increasing healthcare costs: can we influence the costs of glaucoma care?

Marc Töteberg-Harms1, Michael S Berlin, Frances Meier-Gibbons

  • 1aDepartment of Ophthalmology, University Hospital Zurich, Zurich, Switzerland bGlaucoma Institute of Beverly Hills, West Hollywood cUniversity of California Los Angeles Stein Eye Institute, Los Angeles, California, USA dEye Center Rapperswil, Rapperswil, Switzerland.

Insights

Improving patient adherence to glaucoma treatment is key to controlling rising healthcare costs. Further research comparing diagnostic and therapeutic strategies can help reduce expenses for this irreversible blindness condition.

Area of Science:

  • Ophthalmology
  • Health Economics

Background:

  • Global healthcare costs are escalating, influenced by patient and physician factors.
  • Glaucoma, a leading cause of irreversible blindness, necessitates chronic treatment with often low patient adherence.
  • Treatment costs for glaucoma are a significant concern for patients and healthcare systems.

Purpose of the Study:

  • To identify strategies for controlling the rising costs associated with glaucoma care.
  • To review existing literature on factors influencing glaucoma treatment expenses.
  • To explore potential solutions for cost reduction in managing glaucoma.

Main Methods:

  • Systematic review of studies related to glaucoma care costs.
  • Categorization of studies into diagnostic costs, treatment comparisons, patient factors, and general cost aspects.
  • Analysis of theoretical models and calculations regarding healthcare expenses.

Main Results:

  • Studies were categorized into diagnostic costs, treatment comparisons (drugs, laser, surgery), patient adherence, and theoretical cost models.
  • Patient-related factors, particularly adherence, significantly impact treatment costs.
  • Direct cost comparisons between different treatment modalities were examined.

Conclusions:

  • Improving patient adherence to glaucoma treatment is a critical factor in reducing healthcare costs.
  • Cross-country cost comparisons are challenging due to diverse healthcare systems and cultural factors.
  • Further research, including theoretical models and patient studies, is needed to optimize diagnostic and therapeutic scenarios for cost reduction.
Abstract

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
154
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
785
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
10.5K